Preliminary results from another phase I trial combining durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) in NSCLC patients showed an overall response rate of 25 %, and the interesting finding that this efficacy did not depend on PD-L1 expression in the tumor [84]. This evidence concerns the gene CTLA4 and neoplasm.